128140-12-5

Usage

InChI:InChI=1/C31H47N3O7/c1-19(2)15-23(33)27(39)30(18-35,34(7)29(41)25(37)17-21(5)6)31(26(38)13-14-32,22-11-9-8-10-12-22)28(40)24(36)16-20(3)4/h8-12,18-20,23-25,36-37H,5,13-17,32-33H2,1-4,6-7H3/t23-,24?,25-,30-,31?/m0/s1

Upstream product

• 160036-90-8 (S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoic acid (S)-3-methyl-1-{methyl-[(S)-2-phenyl-1-(2,2,2-trichloro-ethoxycarbonyl)-ethyl]-carbamoyl}-butyl ester 
• 160036-93-1 (S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoic acid (S)-1-({(S)-1-[2-((R)-1-carboxy-3-methyl-butoxycarbonyl)-ethylcarbamoyl]-2-phenyl-ethyl}-methyl-carbamoyl)-3-methyl-butyl ester 
• 160036-91-9 (S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoic acid (S)-1-[((S)-1-carboxy-2-phenyl-ethyl)-methyl-carbamoyl]-3-methyl-butyl ester 
• 160036-88-4 (S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoic acid (S)-1-benzyloxycarbonyl-3-methyl-butyl ester 
• 55739-20-3 benzyl (2R)-2-(3-tert-butoxycarbonylaminopropionyloxy)-4-methylpentanoate 
• 37755-48-9 benzyl (2S)-2-hydroxy-4-methylpentanoate 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 137393-05-6 N-((1,1-Dimethylethoxy)carbonyl)-N-methyl-L-phenylalanine phenylmethyl ester 
• 47091-20-3 N-Methyl-L-phenylalanine phenylmethyl ester 
• 37553-65-4 Boc-N-Me-Phe-OH 
• 61-90-5 L-leucine 
• 168070-01-7 Diphenylmethyl (2S)-2-hydroxy-4-methylpentanoate 
• 168069-99-6 Diphenylmethyl (2R)-2-hydroxy-4-methylpentanoate 
• 168070-05-1 N-((1,1-Dimethylethoxy)carbonyl)-β-Ala-O-D-Leu-L-Leu-O-L-Leu-N(Me)-L-Phe phenylmethyl ester 

Relevant academic research and scientific papers

Synthesis and evaluation of backbone/amide-modified analogs of leualacin

Leualacin (1), a cyclic depsi-pentapeptide, and its backbone/amidemodified analogs 2-4 were synthesized. Amide analogue 3 exhibited stronger vasodilatory effects. It also strongly inhibited collagen- and arachidonic acid (AA)induced platelet aggregations with IC50s of 0.6 μM and 2.0 μM, respectively.

Total synthesis of the cyclic depsipeptide leualacin

The fungal metabolite leualacin (1), a potent calcium channel antagonist, was synthesized in 15 steps from commercially available amino acids in 25% overall yield using standard solution methods. The synthesis is general and thus would accommodate the incorporation of amino acid replacements as well as the inclusion of peptide mimics and isosteres.

The Synthesis of Leualacin

Leualacin, a new calcium blocker isolated from Hapsidospora irregularis, has now been synthesized.